Literature DB >> 18064485

Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Sebastian Niedźwiecki1, Tomasz Stepień, Krzysztof Kuzdak, Henryk Stepień, Roman Krupiński, Daniel Seehofer, Nada Rayes, Frank Ulrich.   

Abstract

BACKGROUND AND AIMS: There is growing evidence that cytokines and their antagonists are important in the pathogenesis of various malignancies. While there are several reports on interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and tissue expression, there is only little data available on the impact of IL-1ra serum levels. Therefore, we performed a prospective study, analyzing IL-1ra in thyroid cancer patients.
MATERIALS AND METHODS: We measured preoperative IL-1ra serum levels of 52 consecutive patients with thyroid cancer, 15 with benign adenoma and 27 healthy volunteers. The final histological diagnosis revealed 21 patients with papillary and 8 patients with follicular carcinoma (FTC), while 12 cases of medullary and 11 cases of anaplastic carcinoma (ATC) were observed.
RESULTS: Compared to the control group, serum concentrations of IL-1ra were significantly higher in ATC and FTC patients. Concerning gender differences, this effect reached significance only in women with ATC and FTC. Except for the stage IV disease in ATC, there was no correlation between IL-1ra levels and International Union Against Cancer staging.
CONCLUSION: The findings of our study indicate that IL-1ra may play an important role in the development of ATC and FTC. Future efforts should focus on the possible application of IL-1ra as a biomarker for the above-mentioned thyroid malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18064485     DOI: 10.1007/s00423-007-0251-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  41 in total

Review 1.  Interleukin-1: biology, pathophysiology, and clinical prospects.

Authors:  L C Platanias; N J Vogelzang
Journal:  Am J Med       Date:  1990-11       Impact factor: 4.965

2.  Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients.

Authors:  H Ito; C Miki
Journal:  Scand J Gastroenterol       Date:  1999-11       Impact factor: 2.423

3.  Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.

Authors:  Kyoung-Mu Lee; Sue Kyung Park; Nobuyuki Hamajima; Kazuo Tajima; Ji-Yeob Choi; Dong-Young Noh; Sei-Hyun Ahn; Keun-Young Yoo; Ari Hirvonen; Daehee Kang
Journal:  Breast Cancer Res Treat       Date:  2005-11-30       Impact factor: 4.872

4.  Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers.

Authors:  R Fujiwaki; T Hata; K Miyazaki; T Kawamura; K Inada
Journal:  Br J Obstet Gynaecol       Date:  1997-12

5.  Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.

Authors:  M A Rogy; S M Coyle; H S Oldenburg; C S Rock; P S Barie; K J Van Zee; C G Smith; L L Moldawer; S F Lowry
Journal:  J Am Coll Surg       Date:  1994-02       Impact factor: 6.113

6.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice.

Authors:  E Hirsch; V M Irikura; S M Paul; D Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; T J Standiford; S W Chensue; M W Rolfe; M B Orringer; R I Whyte; M D Burdick; J M Danforth; A R Gilbert
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

8.  Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer.

Authors:  J Sehouli; A Mustea; D Koensgen; F C-K Chen; W Lichtenegger
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

9.  Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis.

Authors:  A M Prieur; M T Kaufmann; C Griscelli; J M Dayer
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

10.  Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor.

Authors:  R W Janson; K R Hance; W P Arend
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

View more
  5 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients.

Authors:  Shailendra Kapoor
Journal:  Langenbecks Arch Surg       Date:  2008-09-30       Impact factor: 3.445

Review 3.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

4.  Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Shijie Xin; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

Review 5.  Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice.

Authors:  Chuang Xi; Guo-Qiang Zhang; Zhen-Kui Sun; Hong-Jun Song; Chen-Tian Shen; Xiao-Yue Chen; Jian-Wen Sun; Zhong-Ling Qiu; Quan-Yong Luo
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.